- Company
- Belgium approved Expanded access of Remimazolam
- by Lee, Seok-Jun Aug 7, 2020 06:26am
- Hana Pharm announced on the 4th that the new drug anesthetic drug 'Remimazolam' was approved by the Federal Agency for Medicines and Health Products of Belgium for sympathetic use for COVID-19 critically ill patients. In recent years, the supply shortage of Propofol and Midazolam for the treatment of critically ill patients with COVID-19 h
- Company
- AstraZeneca’s love for Korea expressed through investment
- by Lee, Seok-Jun Aug 5, 2020 06:26am
- A British-based multinational pharmaceutical company AstraZeneca is expanding its investment in the South Korean pharmaceutical industry. Recently, the company inked a deal with SK Bioscience on supplying COVID-19 vaccine as it saw the promising potential of the Korean industry. AstraZeneca’s investment on the Korean pharmaceutical indus
- Company
- Tecentriq can be prescribed at Big 5 hospitals
- by Eo, Yun-Ho Aug 5, 2020 06:25am
- The indication for triple negative breast cancer of the immuno-cancer drug'T-Sentric' is expanding. According to the related industry, Tecentriq 850mg used for triple-negative breast cancer (TNBC) passed the drug commitee (DC) at 20 major hospitals nationwide, including the Big 5 General Hospital, including Seoul National University Hospit
- Company
- Eisai’s lifestyle app HeLpy for living the healthier life
- by Eo, Yun-Ho Aug 5, 2020 06:25am
- Eisai Korea reported their employees are enjoying the ‘Healthier HeLpy Life’ with the company’s personal lifestyle app ‘HeLpy’ launched in January. The employees health-conscious life started as the company decided to manage their health amid COVID-19, when the busy employees struggled to keep themselves healthy with restricted phys
- Company
- Indications for Keytruda·Tecentriq are actively expanding
- by Eo, Yun-Ho Aug 5, 2020 06:24am
- Expansion of indications for immunocancer drugs continues. According to the related industry, MSD Korea recently obtained the approval for the expansion of indications of inhibitor 'Keytruda (Pembrolizumab)' in head and neck cancer, and Roche Korea's PD-L1 inhibitor 'Tecentriq (Atezolizumab)' in liver cancer. Keytruda can be prescribed f
- Company
- Lurbinectedin by Boryung has been granted orphan drug
- by Lee, Seok-Jun Aug 5, 2020 06:24am
- Boryung announced on the 3rd that the new small cell lung cancer (SCLC) drug Lurbinectedin has been granted orphan drug designation from the MFDS for the treatment of patients with small cell lung cancer (SCLC) Lurbinectedin is indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progressio
- Company
- COVID-19 pandemic crushes Big Pharma sales in Q2
- by An, Kyung-Jin Aug 4, 2020 05:54am
- Heavily impacted by COVID-19 pandemic, the Big Pharma’s second quarter performances have been underwhelming to say the least. As the World Health Organization (WHO) declared the COVID-19 pandemic on Mar. 11, the number of confirmed cases in the U.S. and Europe has exponentially surged and created a gap in pharmaceutical prescription. B
- Company
- Chong Kun Dang has maintained its highest performance
- by Lee, Seok-Jun Aug 4, 2020 05:54am
- Chong Kun Dang has maintained its highest performance in the past five years. During that period, the appearance was almost doubled as a large pharmaceutical company. The operating margin remained around 8% while increasing R&D. Meanwhile, R&D performance is also becoming visible. Chong Kun Dang's virtuous cycle is expected to continue as thi
- Company
- Sales of Duvie exceeded ₩10 billion in the first half
- by Chon, Seung-Hyun Aug 4, 2020 05:54am
- Chong Kun Dang's developed diabetes drug 'Duvie' exceeded the prescription record of &8361;10 billion in the first half. It is strengthening its market competitiveness with the combination drug 'Duvimet'. According to UBIST on the 31st, the total amount of outpatient prescriptions for Duvie in June increased by 5.9% year-on-year to &8361;1
- Company
- Study of Statins vs Ezetimibe combination therapy is ongoing
- by Eo, Yun-Ho Aug 3, 2020 11:06am
- Studies are being conducted to directly compare Statin monotherapy and Ezetimibe combination therapy to Koreans. Yang-Soo Jang, professor at Yonsei University Severance Hospital, conducted a study comparing the efficacy of high-dose Statins and Ezetimibe combination therapy in primary therapy in patients with dyslipidemia with cardiovascul
